Despite widespread optimism about the tax cut bill racing through Congress, biopharma insiders across the U.S. say they’re not expecting to add new jobs at their companies in the coming year, a new STAT Plus survey finds.

Nearly 6 in 10 respondents said it’s unlikely their companies will be expanding. Nonetheless, they remain bullish on the industry at large, with more than half expressing strong confidence that biotech will have a good year.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy